Novosom is working with its partners to develop unique antisense, DNAi and siRNA based therapeutics with a current focus in inflammation, oncology and liver diseases. novosom AG developed a pioneering, fully charge-reversible liposomal technology for the delivery of RNA based therapeutics. SMARTICLES® allow the delivery of siRNA, antisense or decoy oligonucleotides inside the cell for either topical or systemic applications. As of July 27th, 2010 novosom has sold its SMARTICLES® technology to Marina Biotech, Inc.